GateHouse Bio (fka sRNAlytics)
We believe there is an RNA code that drives every disease
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- gatehousebio.com
- Total Funding
- $5.7M
- Last Round
- $250K SeedApr 2018
About
GateHouse Bio is a TechBio company that uses AI to decode small RNA (sRNA) isoforms and develop biomarker-guided precision oligonucleotide therapeutics. Its proprietary Code-Breaker™ platform digitally designs targeted therapies for pulmonary, cardiac, neurological, and autoimmune diseases. The company seeks research collaborators, biopharma partners, and investors to advance its lead programs into human clinical trials.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account